| Name | Title | Contact Details |
|---|
Meet Twiage: An award-winning mobile communication technology that enables hospitals and EMS to accelerate life-saving emergency care by reducing the need of radio and phone communication. Twiage offers Hospitals & Emergency Departments: - Real-time prehospital clinical data for Stroke, STEMI, Trauma, and Sepsis, as well as all other EMS transports - HIPAA-compliant Videos, Photos, and EKGs - Patient Pre-Registration - GPS-tagged ETA for every incoming ambulance, optimizing ED flow and triage - Two-way communication capabilities for intra-hospital care coordination and inter-facility transfers. Twiage offers EMS: - Faster handoffs and ED turnaround times - No more reliance on radios! - HIPAA-compliant video, photos, and data capture sent directly to entire hospital teams - Simple, evidence-driven algorithms that help improve quality handoffs - Ability to create custom algorithms to match your clinical protocols Awards: Pulse @ MassChallenge, Platinum Award, 2017 MATTER Chicago, Observation Unit Challenge - Winner, 2017 American Heart/Stroke Association, Health Tech Competition - People`s Choice Award, 2016 American Medical Association, Healthier Nation Challenge - 1st Place Winner, 2016 Aspen Institute, Spotlight Health Finalist, 2016 Cornell Venture Challenge - 2nd Place Winner, 2016 Cleveland Clinic, New Ventures Healthcare Challenge - Winner, 2015 Massachusetts Medical Society, Information Technology Award, 2014 mHealth, Rockstar of the Year for most meaningful mobile health technology, 2014
Advanced O&P Solutions is a Hickory Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Access Case Management Services of Georg is a Savannah, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hattiesburg Clinic is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Hattiesburg Clinic is based in Hattiesburg, MS. You can find more information on Hattiesburg Clinic at www.hattiesburgclinic.com
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.